Effects of adenosine A1 and A2A receptor activation on the evoked release of glutamate from rat cerebrocortical synaptosomes
Open accessThe DOI matches its Crossref record.
Abstract
1. The effects of adenosine A2A and A1 receptor activation on the release of glutamate were studied in rat cerebral cortex synaptosomes exposed in superfusion to adenosine receptor ligands. 2. Adenosine (0.1 microM) produced a significant potentiation of the Ca2+-dependent K+ (15 mM)-evoked [3H]-D-aspartate overflow (20.4+/-3.5%), which was blocked by A2A blocker SCH58261 (0.1 microM). At higher concentrations (10 - 1000 microM) adenosine inhibited in a DPCPX-sensitive manner the Ca2+-dependent K+-evoked [3H]-D-aspartate overflow. The inhibitory effect of adenosine at 1000 microM was significantly increased by SCH58261. This inhibition was antagonized by 1 microM DPCPX. Adenosine did not produce any effect on basal release. 3. The A2A receptor agonist CGS 21680 was ineffective on basal release, but stimulated the Ca2+-dependent K+-evoked overflow of [3H]-D-aspartate (EC50 approximately 1 pM). The effect of 0.01 nM CGS 21680 was totally sensitive to the A2A receptor antagonist SCH58261 (IC50 approximately 5 nM). 4. The A1 receptor agonist CCPA inhibited the Ca2+-dependent K+-evoked [3H]-D-aspartate overflow (EC50 approximately 20 nM). The effect of 100 nM CCPA was abolished by 100 nM of the A1 receptor antagonist DPCPX. 5. The K+ (15 mM)-evoked overflow of endogenous glutamate was enhanced by CGS 21680 (0.01 nM) and inhibited by CCPA (0.1 microM). The effect of CGS 21680 was abolished by SCH58261 (0.1 microM) and that of CCPA by DPCPX (0.1 microM). 6. It is concluded that adenosine and adenosine receptor agonists modulate glutamate release by activating inhibitory A1 and excitatory A2A receptors present on glutamatergic terminals of the rat cerebral cortex.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Physiology and Pathophysiology of Purinergic Neurotransmission
Burnstock, G. (2007) · Physiological Reviews · doi:10.1152/physrev.00043.2006 · Cited by 1,585
A Review of Caffeine’s Effects on Cognitive, Physical and Occupational Performance
McLellan, T. M., Caldwell, J. A., & Lieberman, H. R. (2016) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2016.09.001 · Cited by 840
Fredholm, B. B., Chen, J.-F., Cunha, R. A., Svenningsson, P., & Vaugeois, J.-M. (2005) · International Review of Neurobiology · doi:10.1016/s0074-7742(05)63007-3 · Cited by 692
Neuroprotection by adenosine in the brain: From A1 receptor activation to A2A receptor blockade
Cunha, R. A. (2005) · Purinergic Signalling · doi:10.1007/s11302-005-0649-1 · Cited by 537
How does adenosine control neuronal dysfunction and neurodegeneration?
Cunha, R. A. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13724 · Cited by 441
Targeting adenosine A2A receptors in Parkinson's disease
Schwarzschild, M. A., Agnati, L., Fuxe, K., Chen, J.-F., & Morelli, M. (2006) · Trends in Neurosciences · doi:10.1016/j.tins.2006.09.004 · Cited by 433
Genetics of caffeine consumption and responses to caffeine
Yang, A., Palmer, A. A., & de Wit, H. (2010) · Psychopharmacology · doi:10.1007/s00213-010-1900-1 · Cited by 309
Ullrich (2018) · doi:10.1038/mp.2017.188 · Cited by 145
Caffeine and the Control of Cerebral Hemodynamics
Pelligrino, D. A., Xu, H.-L., & Vetri, F. (2010) · Journal of Alzheimer's Disease · doi:10.3233/jad-2010-091261 · Cited by 93
Lazarevic, V., Yang, Y., Flais, I., & Svenningsson, P. (2021) · Molecular Psychiatry · doi:10.1038/s41380-021-01246-3 · Cited by 81
Metadata
- Authors
- Marchi, M., Raiteri, L., Risso, F., Vallarino, A., Bonfanti, A., Monopoli, A., Ongini, E., & Raiteri, M.
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 2002-09
- Volume
- 137
- Issue
- 2
- Pages
- 294-294
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- OpenAlex
- W1985556856
- Cited by
- 91
- References
- 0
- FWCI
- 4.47
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.